WP
AXSM icon

Woodline Partners’s Axsome Therapeutics AXSM Stock Holding History

Woodline Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.7M Hold
162,221
– – 0.12% 220
2026
Q1 		$27.4M Buy
162,221
+11,357
+8% +$1.96M 0.1% 264
2025
Q4 		$27.6M Sell
150,864
-181,000
-55% -$25.3M 0.11% 250
2025
Q3 		$40.3M Buy
331,864
+733
+0.2% +$82.6K 0.19% 149
2025
Q2 		$34.6M Buy
331,131
+27,047
+9% +$2.86M 0.18% 155
2025
Q1 		$35.5M Sell
304,084
-104,357
-26% -$11.9M 0.23% 137
2024
Q4 		$34.6M Buy
408,441
+109,872
+37% +$10.1M 0.23% 135
2024
Q3 		$26.8M Sell
298,569
-19,442
-6% -$1.7M 0.23% 145
2024
Q2 		$25.6M Sell
318,011
-42,117
-12% -$3.12M 0.24% 131
2024
Q1 		$28.7M Sell
360,128
-202,035
-36% -$17M 0.26% 117
2023
Q4 		$44.7M Buy
562,163
+110,056
+24% +$7.36M 0.49% 61
2023
Q3 		$31.6M Buy
452,107
+12,182
+3% +$911K 0.37% 66
2023
Q2 		$31.6M Sell
439,925
-130,900
-23% -$9.66M 0.37% 71
2023
Q1 		$35.2M Buy
570,825
+347,173
+155% +$22.8M 0.48% 51
2022
Q4 		$17.3M Buy
+223,652
New +$13.4M 0.23% 132

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Woodline Partners's AXSM Position: Q2 2026 in Review

Woodline Partners held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 162,221 shares worth $39.7M. The position accounts for 0.12% of the portfolio, ranked #220.

Woodline Partners first reported a position in AXSM in Q4 2022 and has held it in 15 quarters since. The position peaked at $44.7M in Q4 2023. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Woodline Partners held 162,221 shares of Axsome Therapeutics worth $39.7M as of Q2 2026.
  • Woodline Partners left its Axsome Therapeutics share count unchanged in Q2 2026.
  • Axsome Therapeutics made up 0.12% of Woodline Partners's portfolio in Q2 2026, its #220 holding.
  • Woodline Partners first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Woodline Partners's Axsome Therapeutics position peaked at $44.7M in Q4 2023.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.